Meeting Demands Of Accelerated Timelines Using Solid Form Screening And Rapid Formulation Selection

Several factors in the pharmaceutical industry are driving the need to reduce the development time from concept to Phase 1 trials. This includes funding models, market competition, and a focus on small targeted populations. Increasingly complex drug compounds, such as specialized products and orphan medications, are exacerbating this by calling on specialized skill sets and technologies to meet target product profiles. With 63% of all new prescription drugs in the last five years coming from small biotechs¹, the need for external partners is on the rise.

As a result, it is more important than ever to find a qualified CDMO that can streamline the development pathway, particularly for APIs with challenging properties such as complex syntheses, challenging physical properties, and/or low aqueous solubility and poor bioavailability. That is why Lonza has developed its integrated service package, SimpliFiH^® Solutions, which offers a combination of targeted testing and basic scientific principles to accelerate development of a preferred synthetic route, a progressible solid form, and a commercially viable formulation in early drug development.